EuroPCR 2026: Reflow Medical Reports "Encouraging" Six-Month Results From DEEPER CORONARY Study

EuroPCR 2026: Reflow Medical reports "encouraging" six-month results from DEEPER CORONARY study

The first six-month clinical results from the DEEPER CORONARY study were presented at EuroPCR 2026 (19–22 May, Paris, France), Reflow Medical has announced. The study evaluates the investigational coronary Spur Elute sirolimus-eluting retrievable stent system for coronary in-stent restenosis (ISR). The data were presented by Scott Harding (Wellington Hospital, Wellington, New Zealand), principal investigator for the DEEPER CORONARY trial. DEEPER…

Reflow Medical has positive data for coronary drug-eluting stent

The Spur Elute stent [Image courtesy of Reflow Medical]Reflow Medical today announced the first six-month clinical results from a study of its Spur Elute sirolimus-eluting retrievable stent system. San Clemente, California-based Reflow designed its stent system to transfer a proprietary drug formulation to the diseased lesion without leaving a permanent metallic implant behind. The device’s retrievable scaffold therapy creates channels to increa…